Investigational Vaccine Has Non-Inferior Immune Response Compared to PCV20 for Pneumococcal Disease
December 13th 2023Clinical trial results show the immunogenicity, tolerability, and safety of V116 compared to a pneumococcal 20-valent conjugate vaccine for adults who had not previously received a pneumococcal vaccine.
Read More
Disparities Across European NEAT ID Centers Impact Implementation, Roll-Out of PrEP
December 13th 2023Both individual and structural barriers were the most common hindrances to PrEP roll-out, and the investigators emphasize that efforts to remove the obstacles as well as further research can help improve PrEP implementation.
Read More
Tirzepatide Results in Superior Mean Percent Change in Body Weight for Those with Obesity
December 13th 2023In the phase 3 SURMOUNT-4 trial, investigators included individuals with at least 1 weight-related complication, including hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
Read More
MAPS PBC Submits NDA to the FDA for MDMA-Assisted Therapy for PTSD
December 12th 2023An FDA approval of 3,4-Methylenedioxy-methamphetamine (MDMA)–assisted therapy would require the Drug Enforcement Administration to reschedule MDMA in acknowledgement of its medical use, making it available for prescription medical use.
Read More
High-Risk Pediatric Patients With Antiphospholipid Syndrome Present Risk of Severe Health Issues
December 11th 2023The results found that 93% of individuals in the high-risk group presented persistently positive antiphospholipid antibodies, compared with 47% of individuals in the lower-risk group.
Read More